Osteoporosis Drugs

The FDA has asked manufacturers of oral bisphosphonate osteoporosis drugs to include warnings that the drugs have a risk of atypical fractures of the femur.

This new warning will bring about label changes for Fosamax, Fosamax Plus D, Actonel, Actonel with Calcium, Boniva, Atelvia and Reclast and any generic versions of these drugs.

Lawsuits continue involving Aredia, Fosamax and Zometa.